BrueraE, MacDonaldRN. Asthenia in patients with advanced cancer. J Pain Sympt Man1988; 3: 9–14.
2.
TheologidesA.Anorexins, asthenins, and cachectins in cancer. Am J Med1986; 81: 696–698.
3.
StiefelF, MorantR, SennHJ. Asthenie bei Tumorkranken — eine Uebersicht. (submitted for publication).
4.
BrueraE, BrenneisC, MichaudM, . Association between involuntary muscle function and asthenia, nutritional status, lean body mass, psychometric assessment and tumor mass in patients with advanced cancer. Proc Am Soc Clin Oncol1987, 6: 261.
5.
SimonsonE.Physiology of work capacity and fatigue. Springfield, Illinois: Charles C Thomas, 1971: 5–6.
6.
WaterhouseC.Lactate metabolism in patients with cancer. Cancer1974; 33: 66–71.
7.
ArnoldD, BoreP, RaddaG, . Excessive intracellular acidosis of skeletal muscle on exercise in a patient with a postviral exhaustion/fatigue syndrome. Lancet1984; i: 1367–1369.
8.
LopesJ, RussellD, WhitewellJ, . Skeletal muscle function in malnutrition. Am J Clin Nutr1983; 36: 602–610.
9.
BrueraE, BrenneisC, MichaudM, . Association between asthenia and nutritional status, lean body mass, anemia, psychological status and tumor mass in patients with advanced breast cancer. J Pain Sympt Man1989; 4: 59–63.
10.
LowrySF. Cancer cachexia revisited: Old problems and new perspectives. Eur J Cancer1991; 27: 1–3.
11.
BeutlerB, CeramiA.Cachectin: more than a tumor necrosis factor. N Engl J Med1987; 316: 379–385.
MoldawerLL, DrottC, LundholmK.Monocytic production and plasma bioactivity of interleukin-1 and tumour necrosis factor in human cancer. Eur J Clin Invest1988; 18: 486–492.
14.
CarswellEA, OldLJ, KasselRL, . An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA1975; 72: 3666–3670.
15.
AggarwalBB, KohrWJ, KassPE, . Human tumor necrosis factor. Production, purification and characterization. J Biol Chem1985; 260: 2345–2354.
16.
EndresS, van der MeerJWM, DinarelloCA. Zytokine in der Pathogenese des Fiebers. Internist1989; 30: 358–362.
17.
DinarelloCA. Interleukin-1: Amino acid sequences, multiple biological activities, and comparison with tumor necrosis factor (cachectin). Year Immunol1986; 2: 68–69.
18.
AdamsF, QuesadaJR, GuttermanJU. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA1984; 252: 938–941.